FULC Share Price Performance
US$6.73
3.85 (133.68%)
64.6% undervalued intrinsic discount
US$19.00
Fair Value
Price US$6.73
AnalystConsensusTarget US$19.00
AnalystHighTarget US$25.00
Fair ValueUS$19.00
Share Pricen/a
Fulcrum Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
FULC Community Narratives
AN
Fair Value US$19 64.6% undervalued intrinsic discount
Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$25 73.1% undervalued intrinsic discount
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$25
73.1% undervalued intrinsic discount
Fair Value
Profit Margin
39.96%
Future PE
38.74x
Price in 2029
US$0
Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on developing oral fetal hemoglobin inducers for sickle cell disease and other hemoglobinopathies. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$19
64.6% undervalued intrinsic discount
Fair Value
Profit Margin
21.47%
Future PE
158.92x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Fair Value: US$25 73.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Fair Value: US$19 64.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Fulcrum Therapeutics, Inc. Key Details
About FULC
- Founded
- 2015
- Employees
- 55
- CEO
- WebsiteView website
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Recent FULC News & Updates
